2. Signaling Pathways
  3. Cytoskeleton
  4. Myosin

Myosin

Myosin

Related Products

PDF 0.33 MB

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152206
    JB062
    		Inhibitor
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB062
  • HY-P10346
    smMLCK peptide
    		Inhibitor
    smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction.
    smMLCK peptide
  • HY-P2162
    Kemptamide
    Kemptamide, a 13 amino acid fragment with a sequence corresponding to residues 11-23 of gizzard light chain. Kemptamide is a peptide substrate of myosin light-chain kinase (MLCK).
    Kemptamide
  • HY-109128S2
    Danicamtiv-d3-1
    Danicamtiv-d3-1 (MYK-491-d3-1) is a deuterated labeled Danicamtiv (HY-109128). Danicamtiv (MYK-491), an inotropic agent, is a selective allosteric activator of cardiac myosin. Danicamtiv increases cardiac systolic function and preserves mechanical efficiency.
    Danicamtiv-d<sub>3</sub>-1
  • HY-122200
    Phenamacril
    		Inhibitor
    Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species.
    Phenamacril
  • HY-174406
    MT-125
    		Inhibitor
    MT-125 is a specific and well-tolerated inhibitor of non-muscle myosin IIA (Ki,NMIIA = 2.7 μM) and IIB (EC50 = 1.7 μM). MT-125 can pass through the blood-brain barrier. MT-125 induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 can enhance the PDGFR signaling pathway. MT-125 can be used for research on glioblastoma.
    MT-125
  • HY-175188
    MT-110
    		Inhibitor
    MT-110 is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor with wide safety margins. MT-110 markedly improves tolerability by selectively targeting NMII over CMII. MT-110 can be used the study of neurological disease.
    MT-110
  • HY-123634
    (S)-3'-Aminoblebbistatin
    		Inhibitor
    (S)-3'-Aminoblebbistatin is the derivative of Blebbistatin (HY-13813). (S)-3'-Aminoblebbistatin exhibits inhibitory activity against myosin II with an IC50 of 14.1 µM.
    (S)-3'-Aminoblebbistatin
  • HY-143657
    Myoferlin inhibitor 1
    		99.88%
    Myoferlin inhibitor 1 is a novel agent against pancreatic cancer metastasis through targeting myoferlin.
    Myoferlin inhibitor 1
  • HY-152190
    JB002
    		Inhibitor 99.32%
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB002
  • HY-141810
    MT-134
    		Inhibitor
    MT-134 is a SkMII-specific inhibitor and has excellent exposure in muscles.
    MT-134
  • HY-100984A
    HA-100 hydrochloride
    		Inhibitor
    HA-100 hydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor.
    HA-100 hydrochloride
  • HY-175199
    MT-228
    		Inhibitor
    MT-228 is a selective and blood-brain barrier permeable non-muscle myosin II inhibitor. MT-228 markedly improves tolerability by selectively targeting NMIIB (KI = 1.5 μM) over CMII (KI = 17 μM), and the sequence of SmMll MD is 83.6% identical to that of NMllB. MT-228 shows long-lasting efficacy in animal models of stimulant use disorder.
    MT-228
  • HY-13441G
    (-)-Blebbistatin (GMP)
    		Inhibitor
    (-)-Blebbistatin (GMP) is (-)-Blebbistatin (HY-13441) produced by using GMP guidelines. (-)-Blebbistatin (GMP) is a selective inhibitor of the ATPase activity of non-muscle myosin II.
    (-)-Blebbistatin (GMP)
  • HY-128482
    Diazobenzenesulfonic acid
    		Inhibitor
    Diazobenzenesulfonic acid (4-Sulfobenzenediazonium) is an inhibitor of aliostericeffect for myosin ATPase 13.
    Diazobenzenesulfonic acid
  • HY-12880
    HA-100 dihydrochloride
    		Inhibitor
    HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor.
    HA-100 dihydrochloride
  • HY-139622
    DN-F01
    		Inhibitor
    DN-F01 has a strong inhibitory calcium-dependent effect on cardiac myofibrillar ATPase activity with an IC50 value of 11 ± 4 nmol/L.
    DN-F01
  • HY-161608
    Myosin modulator 1
    		Modulator
    Myosin modulator 1 (Compound B141) is a modulator for myosin, that inhibits ATPase in rabbits psoas, porcine atria and in porcine ventricle, with IC25s of 0.42, 0.13 and 3.09 μM, respectively. Myosin modulator 1 regulates systolic cardiac performance in Sprague Dawley rats.
    Myosin modulator 1
  • HY-122200R
    Phenamacril (Standard)
    		Inhibitor
    Phenamacril (Standard) is the analytical standard of Phenamacril. This product is intended for research and analytical applications. Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species.
    Phenamacril (Standard)
  • HY-169183
    Myokinasib-II
    		Inhibitor
    Myokinasib-II is a myosin light chain kinase (MLCK) inhibitor, which is a potential target for inflammatory diseases, cancer and other diseases..
    Myokinasib-II
Cat. No. Product Name / Synonyms Application Reactivity